Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/ 10.14670/HH-18-404

Título: Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?
Fecha de publicación: 2022
Editorial: Universidad de Murcia, Departamento de Biologia Celular e Histiologia
Cita bibliográfica: Histology and Histopathology Vol. 37, nº3 (2022)
ISSN: 0213-3911
1699-5848
Materias relacionadas: CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología
Palabras clave: Adenosine deaminase
Central nervous system
Pathology
Severe combined immunodeficiency
Amyotrophic lateral sclerosis
Resumen: Adenosine deaminase (ADA) is a purine metabolism enzyme that catalyses the breakdown of adenosine and deoxyadenosine. The enzyme is important in several cellular processes, including the innate immune response and cellular differentiation, and it is also an important enzyme for the maintenance of brain homeostasis, in part due to its regulation of adenosine. Aberrant regulation of ADA enzyme activity has been linked to several neurodegenerative diseases and diseases that can result in neurological impairment. However, the mechanisms behind altered ADA regulation and how this leads to the development of neurological dysfunction are poorly characterised. This review summarises the current research on ADA and its role and regulation in disease pathology, with a focus on the central nervous system (CNS) and the neurodegenerative disease, amyotrophic lateral sclerosis (ALS)
Autor/es principal/es: Hall, Benjamin
George, Jonathan G.
Allen, Scott P.
URI: http://hdl.handle.net/10201/128325
DOI: https://doi.org/ 10.14670/HH-18-404
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 24
Derechos: info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Aparece en las colecciones:Vol.37, nº3 (2022)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Hall-37-189-212-2022.pdf4,48 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons